STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

United Therapeutics (UTHR) Rule 144 Notice — 11,000 Shares via Morgan Stanley

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for proposed sale of securities under Rule 144. The filing shows 11,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 08/21/2025 with an aggregate market value of $3,396,248.90 and the issuer reported 45,226,262 shares outstanding. The securities were acquired on 08/21/2025 by stock option exercise and payment was in cash. The filing also lists multiple recent sales by Paul Mahon totaling 66,000 shares in the past three months. The notice includes the standard signature representation that the seller has no undisclosed material adverse information.

Positive

  • Detailed transaction disclosure: The filing lists the exact shares, broker, sale date, and acquisition method, supporting regulatory transparency.
  • Broker identified: Sales are to be executed through Morgan Stanley Smith Barney LLC, providing a clear execution venue.
  • Seller certification included: The signer represents no undisclosed material adverse information, consistent with Rule 144 requirements.

Negative

  • Frequent insider sales: Seven transactions in the past three months total 66,000 shares, increasing available share supply.
  • Missing issuer identification: The provided extract does not state the issuer name in the issuer information section.
  • Partial filer contact data: Submission contact fields in the extract are blank, limiting traceability of the filing origin.

Insights

TL;DR: Insider executed options and repeatedly sold shares; total recent disposals equal 66,000 shares, indicating notable insider liquidity.

The filing documents a Rule 144 notice for 11,000 common shares to be sold via Morgan Stanley on 08/21/2025, acquired the same day via option exercise and paid in cash. The inclusion of seven prior sales by the same person over six weeks is material for share supply; those transactions total 66,000 shares. The filing is procedural and provides transparent transaction detail but does not disclose the issuer name in the provided tables.

TL;DR: The filing meets Rule 144 disclosure requirements but omits issuer identification in the provided extract.

The notice contains the required sale and acquisition details, broker identification, and the seller's certification regarding undisclosed material information, supporting compliance with securities rules. However, the provided content lacks a clearly stated issuer name and some filer contact fields are blank, which reduces clarity for stakeholders reviewing governance and insider activity records.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for UTHR indicate about the proposed sale?

The form indicates 11,000 shares of common stock are proposed to be sold via Morgan Stanley on 08/21/2025 with an aggregate market value of $3,396,248.90.

How were the 11,000 shares acquired according to the filing?

The filing states the shares were acquired on 08/21/2025 through a stock option exercise and payment was made in cash.

Who has sold shares in the past three months according to this filing?

The filing lists sales by Paul Mahon totaling 66,000 shares across seven transactions dated from 05/29/2025 to 08/07/2025.

Does the filing identify the broker executing the sale?

Yes. The broker listed is Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

Is there any undisclosed material information claimed by the seller?

By signing, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

21.03B
42.14M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING